Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00088855
Recruitment Status : Active, not recruiting
First Posted : August 5, 2004
Last Update Posted : March 5, 2018
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Primary Completion Date : October 31, 2006
  Study Completion Date : No date given